Adapting CDMO Capabilities to Support the Development and Commercialization of Orphan Drugs and Novel Therapies

Drug substance
Orphan drugs

As more novel therapies and orphan drugs fill the drug development pipeline, small-scale CDMO capabilities have become an increasingly common need for sponsors developing and commercializing new drug entities. In this webinar, our experts explain how the recent $38 million investment we’ve made at our High Point, NC, facility – including new state-of-the-art technology and laboratory equipment, an energy-efficient infrastructure, and clinical to commercial manufacturing scale – is designed to meet this growing demand.

Key takeaways include:

  • The increasing influx of novel therapies and orphan drugs is reshaping the drug development pipeline
  • The growing necessity for small-scale Contract Development and Manufacturing Organization (CDMO) capabilities among sponsors
  • Learn about Cambrex’s strategic expansion of laboratory and small-scale commercial manufacturing suites designed to cater to orphan and niche therapies